• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by Ii David Anthony Puopolo

    1/15/21 4:21:38 PM ET
    $CVLB
    Get the next $CVLB alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Puopolo Anthony David II

    (Last) (First) (Middle)
    C/O CONVERSION LABS, INC,
    800 THIRD AVENUE, SUITE 2800

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    01/11/2020
    3. Issuer Name and Ticker or Trading Symbol
    CONVERSION LABS, INC. [ CVLB ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Medical Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Options to purchase shares of Common Stock (1) (1) Common Stock, par value $0.001 200,000 (1) D(1)
    Explanation of Responses:
    1. Pursuant to the terms of the employment agreement, by and between Mr. Puoplo and the Issuer, dated January 11, 2021 (the "Effective Date"), Mr. Puopolo was granted stock options to purchase up to 200,000 shares of the Company's common stock at an exercise price of $7.48 per share (the "Stock Options"). 5,555 of the Stock Options shall vest in equal monthly tranches, based on the passage of time, over the 35 months following the approval of the Effective Date, with the remaining 5,575 Stock Options scheduled to vest on January 11, 2024.
    /s/ Anthony Puopolo 01/15/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CVLB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CVLB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CVLB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Conversion Labs Begins Trading Under New Company Name, LifeMD, and Ticker Symbol, LFMD

      NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, will begin trading at the opening of the market today under its new name, LifeMD, Inc., and Nasdaq ticker symbol, LFMD. The stock’s new CUSIP number will be 53216B 104. “Our new name reflects our evolution from a healthcare-focused performance marketing business into a leading provider of personalized, direct to patient telehealth services,” stated Justin Schreiber, LifeMD’s co-founder and CEO. “Our vision is to radically change healthcare by making access to the best physicians and prescription medications easily accessible, convenient, and aff

      2/22/21 3:30:00 AM ET
      $CVLB
    • Conversion Labs to Become Life MD™ with Launch of New Concierge Telehealth Services

      NEW YORK, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-patient telehealth company, will change its name to Life MD™ on February 22, followed by the official launch of its subscription-based primary care and concierge services offering designed to positively transform all aspects of a patient’s healthcare. “We see our new name reflecting our evolution and expansion from a branded telemedicine products company into a leading provider of end-to-end concierge telehealth services,” stated company co-founder and CEO, Justin Schreiber. “Life MD expresses our desire to have a deeper connection to the daily lives of our patients who desire more conven

      2/12/21 8:30:00 AM ET
      $CVLB
    • Conversion Labs Appoints Seasoned Financial and Operational Executive, Marc Benathen, as Chief Financial Officer

      NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-consumer telemedicine company, has appointed Marc Benathen as chief financial officer, effective March 1. He succeeds Juan Manuel Piñeiro Dagnery, who will continue as chief revenue officer. Benathen is an accomplished senior financial and operational executive with 18 years of experience leading multiple areas of finance and operations, including corporate strategy, procurement and supply chain, technology, legal and customer service. He also brings to the company experience in team building and leading complex capital market transactions, M&A and joint ventures, as well as leadership of

      2/5/21 8:31:00 AM ET
      $CVLB

    $CVLB
    SEC Filings

    See more
    • SEC Form 8-K filed

      8-K - LifeMD, Inc. (0000948320) (Filer)

      2/26/21 5:00:48 PM ET
      $CVLB
    • SEC Form 8-K filed

      8-K - CONVERSION LABS, INC. (0000948320) (Filer)

      2/22/21 7:30:16 AM ET
      $CVLB
    • SEC Form 8-K filed

      8-K - CONVERSION LABS, INC. (0000948320) (Filer)

      2/12/21 8:30:10 AM ET
      $CVLB

    $CVLB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Conversion Labs, Inc.

      SC 13D - LifeMD, Inc. (0000948320) (Subject)

      3/19/21 4:15:12 PM ET
      $CVLB

    $CVLB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: David Happy Walters was granted 1,200,000 units of Common Stock, increasing ownership by 149% to 1,336,300 units

      4 - LifeMD, Inc. (0000948320) (Issuer)

      2/26/21 10:04:47 AM ET
      $CVLB
    • SEC Form 4: Harold Eric Yecies bought $100,400 worth of Common Stock (5,000 units at $20.08)

      4 - LifeMD, Inc. (0000948320) (Issuer)

      2/25/21 7:16:47 PM ET
      $CVLB
    • SEC Form 4: Michael Brad Roberts bought $102,500 worth of Common Stock (5,000 units at $20.50)

      4 - LifeMD, Inc. (0000948320) (Issuer)

      2/25/21 6:13:10 PM ET
      $CVLB

    $CVLB
    Leadership Updates

    Live Leadership Updates

    See more
    • Conversion Labs Appoints Seasoned Financial and Operational Executive, Marc Benathen, as Chief Financial Officer

      NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-consumer telemedicine company, has appointed Marc Benathen as chief financial officer, effective March 1. He succeeds Juan Manuel Piñeiro Dagnery, who will continue as chief revenue officer. Benathen is an accomplished senior financial and operational executive with 18 years of experience leading multiple areas of finance and operations, including corporate strategy, procurement and supply chain, technology, legal and customer service. He also brings to the company experience in team building and leading complex capital market transactions, M&A and joint ventures, as well as leadership of

      2/5/21 8:31:00 AM ET
      $CVLB
    • Conversion Labs Appoints Leading Telehealth Professional, Dr. Anthony Puopolo, as Chief Medical Officer

      NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has appointed licensed personal care and wellness physician and psychiatrist, Dr. Anthony Puopolo, to the new position of chief medical officer. Dr. Puopolo will be responsible for overseeing the company’s rapidly expanding network of state licensed physicians and ensuring that the company is delivering the highest quality of care. He will also work closely with Conversion Labs’ product and marketing teams to optimize the company’s telemedicine offerings and support expansion into new verticals. Dr. Puopolo brings to Conversion Labs more than 20 years of execut

      1/11/21 8:31:00 AM ET
      $CVLB
    • Conversion Labs Appoints Digital Marketing Executive, Bryant Hussey, as Chief Digital Officer

      NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has appointed digital marketing expert and industry thought-leader, Bryant Hussey, to the new position of chief digital officer. He will lead the company’s marketing and customer retention efforts, as well as help launch new or enhanced telemedicine products, improve unit economics, and maximize patient lifetime value. Hussey brings to Conversion Labs more than 20 years of executive experience at direct-to-consumer and eCommerce companies, translating business goals into successful marketing campaigns. He specializes in lead generation, funnel optimization and custo

      1/5/21 10:15:00 AM ET
      $CVLB

    $CVLB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research reiterated coverage on Conversion Labs with a new price target

      BTIG Research reiterated coverage of Conversion Labs with a rating of Buy and set a new price target of $40.00 from $15.00 previously

      2/18/21 9:19:07 AM ET
      $CVLB
    • B. Riley FBR initiated coverage on Conversion Labs with a new price target

      B. Riley FBR initiated coverage of Conversion Labs with a rating of Buy and set a new price target of $35.00

      2/5/21 6:59:45 AM ET
      $CVLB